Guidelines for CSF Processing and Biobanking: Impact on the Identification and Development of Optimal CSF Protein Biomarkers

Hok‐A‐Hin, Yanaika S.; Willemse, Eline A.J.; Teunissen, Charlotte E.; Campo, Marta Del

doi:10.1007/978-1-4939-9706-0_2

Cited by 21 publications

(15 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite having extensively been studied for the detection of tumor biomarkers, few of CSF markers have found a clinical application 11 . While there is consensus about the fact that CSF is amenable for the research of biomarkers of neurological disease, literature reports high variability across studies that hinders implementation in clinical practice 58 . Notwithstanding the fforts in identifying novel CSF biomarkers, the high variability observed across different studies has hampered their clinical implementation.…”

Section: Discussionmentioning

confidence: 99%

“…Notwithstanding the fforts in identifying novel CSF biomarkers, the high variability observed across different studies has hampered their clinical implementation. Such variability is partly due to protein stability issues, highlighting the importance to standardize withdrawal procedures 58 . Optimization of protocols for CSF sample collection and treatment have been recently proposed for biomarker studies, although from lumbar puncture 59 .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Potential biomarkers of childhood brain tumor identified by proteomics of cerebrospinal fluid from extraventricular drainage (EVD)

Bruschi

Petretto

Cama

et al. 2021

Sci Rep

View full text Add to dashboard Cite

Brain tumors are the most common solid tumors in childhood. There is the need for biomarkers of residual disease, therapy response and recurrence. Cerebrospinal fluid (CSF) is a source of brain tumor biomarkers. We analyzed the proteome of waste CSF from extraventricular drainage (EVD) from 29 children bearing different brain tumors and 17 controls needing EVD insertion for unrelated causes. 1598 and 1526 proteins were identified by liquid chromatography-coupled tandem mass spectrometry proteomics in CSF control and brain tumor patients, respectively, 263 and 191 proteins being exclusive of either condition. Bioinformatic analysis revealed promising protein biomarkers for the discrimination between control and tumor (TATA-binding protein-associated factor 15 and S100 protein B). Moreover, Thymosin beta-4 (TMSB4X) and CD109, and 14.3.3 and HSP90 alpha could discriminate among other brain tumors and low-grade gliomas plus glyoneuronal tumors/pilocytic astrocytoma, or embryonal tumors/medulloblastoma. Biomarkers were validated by ELISA assay. Our method was able to distinguish among brain tumor vs non-tumor/hemorrhagic conditions (controls) and to differentiate two large classes of brain tumors. Further prospective studies may assess whether the biomarkers proposed by our discovery approach can be identified in other bodily fluids, therefore less invasively, and are useful to guide therapy and predict recurrences.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Potential biomarkers of childhood brain tumor identified by proteomics of cerebrospinal fluid from extraventricular drainage (EVD)

Bruschi

Petretto

Cama

et al. 2021

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Despite widespread use in Europe, studies of these core CSF biomarkers have found significant inter‐laboratory and batch‐to‐batch variability 7,37 . There are three possible sources of variability to be considered when interpreting CSF biomarker results or when defining CSF biomarker cutoffs: (1) pre‐analytical (i.e., due to differences in the collection, handling, and storage of CSF); 38 (2) analytical (i.e., due to differences in technician skill or how the assays are used in the lab, and lot‐to‐lot variability of reference materials, kits and/or kit components); 37,39 and (3) biological/patient‐related (i.e., confounding factors linked to patients, such as patient age).…”

Section: Introductionmentioning

confidence: 99%

“…36 Despite widespread use in Europe, studies of these core CSF biomarkers have found significant inter-laboratory and batch-to-batch variability. 7,37 There are three possible sources of variability to be considered when interpreting CSF biomarker results or when defining CSF biomarker cutoffs: (1) pre-analytical (i.e., due to differences in the collection, handling, and storage of CSF); 38 (2) analytical (i.e., due to differences (C11RMP9 and C12RMP1, respectively). 7,41 Initiatives to obtain standardization of Aβ1-40 and t-tau are ongoing.…”

Section: Introductionmentioning

confidence: 99%

The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau

Hansson

Batrla

Brix

et al. 2021

Alzheimer's & Dementia

Self Cite

View full text Add to dashboard Cite

The core cerebrospinal fluid (CSF) Alzheimer's disease (AD) biomarkers amyloid beta (Aβ42 and Aβ40), total tau, and phosphorylated tau, have been extensively clinically validated, with very high diagnostic performance for AD, including the early phases of the disease. However, between‐center differences in pre‐analytical procedures may contribute to variability in measurements across laboratories. To resolve this issue, a workgroup was led by the Alzheimer's Association with experts from both academia and industry. The aim of the group was to develop a simplified and standardized pre‐analytical protocol for CSF collection and handling before analysis for routine clinical use, and ultimately to ensure high diagnostic performance and minimize patient misclassification rates. Widespread application of the protocol would help minimize variability in measurements, which would facilitate the implementation of unified cut‐off levels across laboratories, and foster the use of CSF biomarkers in AD diagnostics for the benefit of the patients.

show abstract

“…We need to unify the operation of the assays and verify the appropriate criteria of the normal range to be aware of misuse and abuse. Through efforts from global consortiums on biomarkers, the methods and cut-off points of cerebrospinal fluid (CSF) biomarkers in the A-T-N-X framework have been partially aligned in AD, and the quality control program has been established [ 23 ] ( https://www.alz.org/research/for_researchers/partnerships/gbsc ; https://fnih.org/what-we-do/biomarkers-consortium ; https://www.ifcc.org/ ; http://www.neurochem.info/ ). Evaluations of biomarkers in the framework are not limited to a simple dichotomy [ 24 ].…”

Section: Addition Of X To the A-t-n Biomarker Framework To Reflect Th...mentioning

confidence: 99%

Biofluid Biomarkers of Alzheimer’s Disease: Progress, Problems, and Perspectives

2022

View full text Add to dashboard Cite

Since the establishment of the biomarker-based A-T-N (Amyloid/Tau/Neurodegeneration) framework in Alzheimer’s disease (AD), the diagnosis of AD has become more precise, and cerebrospinal fluid tests and positron emission tomography examinations based on this framework have become widely accepted. However, the A-T-N framework does not encompass the whole spectrum of AD pathologies, and problems with invasiveness and high cost limit the application of the above diagnostic methods aimed at the central nervous system. Therefore, we suggest the addition of an “X” to the A-T-N framework and a focus on peripheral biomarkers in the diagnosis of AD. In this review, we retrospectively describe the recent progress in biomarkers based on the A-T-N-X framework, analyze the problems, and present our perspectives on the diagnosis of AD.

show abstract

Guidelines for CSF Processing and Biobanking: Impact on the Identification and Development of Optimal CSF Protein Biomarkers

Cited by 21 publications

References 75 publications

Potential biomarkers of childhood brain tumor identified by proteomics of cerebrospinal fluid from extraventricular drainage (EVD)

Potential biomarkers of childhood brain tumor identified by proteomics of cerebrospinal fluid from extraventricular drainage (EVD)

The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau

Biofluid Biomarkers of Alzheimer’s Disease: Progress, Problems, and Perspectives

Contact Info

Product

Resources

About